Stock Picking Algorithm Based on Deep Learning: Returns up to 14.51% in 14 Days
Stock Picking Algorithm
An insider is legally permitted to buy and sell shares of the firm – and any subsidiaries – that employs him or her. However, these transactions must be properly registered with the Securities and Exchange Commission (SEC) and are done with advance filings. You can find details of this type of insider trading on the SEC’s EDGAR database. This algorithmic forecast is for stocks with recently reported insiders’ transactions.An “insider” is any person who possesses at least one of the following:
- access to valuable non-public information about a corporation (for example a company’s directors and high-level executives)
- ownership of more than 10% of the company’s equity
Package Name: Insiders Stocks
Recommended Positions: Long
Forecast Length: 14 Days (07/30/2018 – 08/13/2018)
I Know First Average: 3.73%
I Know First’s State of the Art Algorithm accurately forecasted 8 out of 10 trades in this Insiders Stocks Package for the 14 Days time period. The greatest return came from PCRX at 14.51%. PCMI and UVE also performed well for this time horizon with returns of 14.29% and 7.60%, respectively. The package itself saw an overall return of 3.73%, providing investors with a 3.62% premium above the S&P 500’s return of 0.11% for the same time period.
Pacira Pharmaceuticals, Inc., incorporated on December 22, 2006, is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product candidate is EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other Food and Drug Administration (FDA)-approved commercial product, DepoCyt(e), which it manufactures for its commercial partners, as well as its product candidates. The Company’s other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA).
Algorithmic traders utilize these daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster. This forecast was sent to current I Know First subscribers.
How to interpret this diagram
Algorithmic Stock Forecast: The table on the left is a stock forecast produced by I Know First’s algorithm. Each day, subscribers receive forecasts for six different time horizons. Note that the top 10 stocks in the 1-month forecast may be different than those in the 1-year forecast. In the included table, only the relevant stocks have been included. The boxes are arranged according to their respective signal and predictability values (see below for detailed definitions). A green box represents a positive forecast, suggesting a long position, while a red represents a negative forecast, suggesting a short position.
Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.